Does EU Approval of Wegovy Pill Change NVO’s Competitive Story?
Novo Nordisk NVO received a meaningful commercial boost last week after the European Commission approved the oral version of…
Can Oral Ozempic and Label Expansions Revive NVO’s Near-Term Growth?
Novo Nordisk NVO is a dominant player in the GLP-1 space, marketing its semaglutide drugs under brand names Ozempic…
Which Healthcare Giant Is the Better Bet?
Novo Nordisk NVO and Pfizer PFE are both pharmaceutical giants based in Denmark and the United States, respectively, with…
How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q3 Results?
Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its…